L1 Endonuclease Inhibitors for Age-Associated Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for better understanding and treatment of age-related inflammation and associated disorders, as current methods are limited in addressing the mechanisms underlying these conditions, particularly the role of senescent cells and the L1 retrotransposable element in chronic diseases.
Innovation Solution
Development of inhibitors targeting the L1 endonuclease (EN) domain to reduce age-associated inflammation by preventing the retrotransposition of the L1 element, thereby reducing proinflammatory factors and DNA damage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If L1 retrotransposition is allowed to proceed naturally, then genomic diversity and evolution are promoted, but age-associated inflammation and DNA damage increase
Solution Approach 1:
The patent targets the harmful retrotransposition activity of L1 elements in aged tissues by designing endonuclease inhibitors that specifically block the EN domain. This converts the potentially harmful retrotransposition process into a controlled state, reducing inflammation while preserving beneficial genomic functions. The inhibitors transform the pathological L1 activity into a harmless or beneficial state by preventing DNA breaks and cytoplasmic DNA accumulation.
2Object-affected harmful factors
If L1 endonuclease activity is inhibited, then age-associated inflammation and DNA damage are reduced, but retrotransposition capability is suppressed
Solution Approach 1:
The patent applies local quality by specifically targeting the endonuclease domain of L1 retrotransposons in aged tissues and senescent cells, rather than globally suppressing all retrotransposition activity. The endonuclease inhibitors selectively block the EN domain's ability to cleave DNA, reducing local damage in tissues where L1 activity is pathological, while potentially preserving retrotransposition capability in germ cells or other contexts where it remains beneficial.
3Adaptability or versatility
If senescent cells accumulate with age, then cellular diversity and tissue function are maintained, but proinflammatory factors and sterile inflammation increase
Solution Approach 1:
The patent extracts and targets the specific pathological mechanism within senescent cells - the derepressed L1 retrotransposition activity - by administering endonuclease inhibitors. This removes the harmful retrotransposition process from senescent cells, reducing their proinflammatory secretory phenotype (SASP) without requiring removal of the senescent cells themselves. The inhibitors extract the harmful L1 activity from the cellular environment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The L1 EN inhibitors effectively prevent or reverse age-associated inflammation, slowing or reversing the progression of diseases such as Alzheimer's and ALS by decreasing proinflammatory markers and DNA damage.
Implementation Method 1
The L1 EN initiates L1 retrotransposition by nicking genomic DNA... inhibitors of the L1 EN that have shown efficacy in a biochemical assay and retrotransposition assay in cells
Data Source
AI summary
Disclosed is a method for preventing, delaying or reversing age-associated inflammation, by administering to a patient in need thereof a therapeutically effective amount of at least one LINE 1 (L-1) endonuclease inhibitor. The age-associated inflammation is associated with an upregulation of L1, an accumulation of cytoplasmic L1 cDNA, an activation of an IFN-I response, and/or a reinforcement of a SASP pro-inflammatory state. The L1 EN inhibitor is administered in an amount sufficient to prevent or reverse at least one of the upregulation L1, the accumulation of cytoplasmic L1 cDNA, the activation of the IFN-I response, and/or the SASP pro-inflammatory state.